AU2002220069A1 - Methods and instruments for treating pseudoarthrosis - Google Patents
Methods and instruments for treating pseudoarthrosisInfo
- Publication number
- AU2002220069A1 AU2002220069A1 AU2002220069A AU2002220069A AU2002220069A1 AU 2002220069 A1 AU2002220069 A1 AU 2002220069A1 AU 2002220069 A AU2002220069 A AU 2002220069A AU 2002220069 A AU2002220069 A AU 2002220069A AU 2002220069 A1 AU2002220069 A1 AU 2002220069A1
- Authority
- AU
- Australia
- Prior art keywords
- bone
- mass
- elongated member
- pseudoarthrotic
- drill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 77
- 208000002607 Pseudarthrosis Diseases 0.000 title claims description 62
- 210000000988 bone and bone Anatomy 0.000 claims description 65
- 230000002138 osteoinductive effect Effects 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 53
- 230000004927 fusion Effects 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 17
- 102100026632 Mimecan Human genes 0.000 claims description 10
- 101800002327 Osteoinductive factor Proteins 0.000 claims description 10
- 239000007943 implant Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 238000000429 assembly Methods 0.000 claims description 8
- 230000000712 assembly Effects 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 7
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 7
- 235000011010 calcium phosphates Nutrition 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 7
- 239000000560 biocompatible material Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 230000008468 bone growth Effects 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 5
- 238000002591 computed tomography Methods 0.000 claims description 5
- -1 hydroxyapatite Chemical compound 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 238000005553 drilling Methods 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 238000002594 fluoroscopy Methods 0.000 claims description 2
- 239000007769 metal material Substances 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims 24
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 11
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 11
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000004568 cement Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102100033337 PDZ and LIM domain protein 7 Human genes 0.000 claims 4
- 101710121660 PDZ and LIM domain protein 7 Proteins 0.000 claims 4
- 229920000954 Polyglycolide Polymers 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 230000000921 morphogenic effect Effects 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 239000004633 polyglycolic acid Substances 0.000 claims 4
- 239000004626 polylactic acid Substances 0.000 claims 4
- 102000014015 Growth Differentiation Factors Human genes 0.000 claims 3
- 108010050777 Growth Differentiation Factors Proteins 0.000 claims 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- 230000007547 defect Effects 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 230000011164 ossification Effects 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 229920005603 alternating copolymer Polymers 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 210000005009 osteogenic cell Anatomy 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 claims 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 claims 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000018386 EGF Family of Proteins Human genes 0.000 claims 1
- 108010066486 EGF Family of Proteins Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims 1
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 101710192602 Latent membrane protein 1 Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000012980 RPMI-1640 medium Substances 0.000 claims 1
- 102000013275 Somatomedins Human genes 0.000 claims 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 241001447056 Uristes Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 229910052586 apatite Inorganic materials 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- 230000033558 biomineral tissue development Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012091 fetal bovine serum Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 230000001599 osteoclastic effect Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000037873 arthrodesis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012978 minimally invasive surgical procedure Methods 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 238000002355 open surgical procedure Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Description
4/11
5/11
Fig. 10B
6/11
Fig. 12
7/11
8/11
9/11
10/11
Fig. 17
11/11
Fig. 18
1
Fig. 19
METHODS AND INSTRUMENTS FOR TREATING PSEUDOARTHROSIS
CROSS-REFERENCE TO RELATED APPLICATION
The present application claims the benefit of United States Provisional Application Serial No. 60/242,950 filed on October 24, 2000, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
The present invention relates generally to methods and instruments for treating pseudoarthrosis.
Back pain affects millions of individuals and is a common cause of disability for the middle-aged worfang population. A frequent cause of back pain is rupture or degeneration of intervertebral discs. In many instances, the only relief from the symptoms of these conditions is a discectomy, or surgical removal of all or a portion of an intervertebral disc. Additionally, the disc space height must be maintained or restored. One solution to the stabilization of an excised disc space is to fuse the adjacent vertebrae between their respective endplates. Typically a spacer or implant is inserted into the treated or prepared disc space until complete arthrodesis is achieved. The spacer/implant must provide temporary support and allow bone ingrowth. Success of the discectomy and fusion procedure requires development of a contiguous growth of bone or an osseous bridge to create a solid mass between the vertebrae to withstand the compressive loads on the spine for the life of the patient.
Several metal spacers have been developed to fill the void formed by the discectomy and to promote fusion. Sofamor Danek Group, Inc., (Memphis, TN) markets a number of hollow spinal cages, and a wide vaπety of other such cages are known in the art. For example, U.S. Patent Nos. 5,015,247 and 5,984,967 to Michelson et al. and Zdeblick et al, respectively,
disclose threaded spinal cages. The cages are hollow and can be filled with osteoinductive material, such as autograft and allograft, prior to insertion into the intervertebral disc space. Apertures defined in the cages communicate with the hollow interior to provide a path for tissue growth between the vertebral endplates.
Although some success with respect to spinal fusions has generally been obtained with respect to interbody fusions or intertransverse process fusions, the incidence of pseudoarthrosis, also known as pseudarthrosis, or failure of a spinal fusion, may be relatively high in certain circumstances. For example, the incidence of pseudoarthrosis has been reported as high as 40% for smokers, as well as for patients having multilevel fusions and unrecognized metabolic disease. Pseudoarthrosis has been shown to be the contributing cause of symptoms in 78% of symptomatic patients requiring reoperation, with each reparative procedure decreasing the probability of success. Moreover, at least about 90% of attempted posterolateral intertransverse process fusions with autogenous iliac crest bone grafting in Lewis rats fail.
In order to treat symptomatic pseudoarthrosis, a conventional, open surgical procedure includes direct exposure of the fusion mass, decortication, bone regrafting and possibly reinstrumentation or addition of new graft and/or new instrumentation. The repair procedure can be very complex, is highly invasive and additional posterior fusion procedures may need to be performed to stabilize the spine after a fusion has failed. Thus, simpler, less invasive methods for treating spinal pseudoarthrosis are needed.
3 SUMMARY OF THE INVENTION
It has been discovered that administration of an osteoinductive composition to a location of pseudoarthrosis, such as spinal pseudoarthrosis, is effective in promoting bone growth for treating the pseudoarthrosis.
Accordingly, in one aspect of the invention, methods of treating spinal pseudoarthrosis are provided.
In one form of the invention, a method includes delivering to a location of pseudoarthrosis an effective amount of an osteoinductive composition. Preferably the osteoinductive composition is combined with an acceptable carrier, such as a calcium phosphate-containing carrier. The osteoinductive composition is effective in promoting bone growth for treating the spinal pseudoarthrosis.
In preferred forms, the method includes advancing a first elongated member to a location of spinal pseudoarthrosis in a patient. The first elongated member has a proximal end, a distal end and a lumen extending longitudinally therethrough. The method further includes advancing the osteoinductive composition described herein through the lumen of the first elongated member. In other preferred forms of the invention, the osteoinductive composition is advanced through the lumen of the elongated member to a pseudoarthrotic mass into and extending across the pesudoarthrotic mass.
The methods described herein may be accomplished with or without decortication and, in the case of a failed interbody fusion, without removal of the implant. Further the methods can use minimally invasive surgical procedures that can significantly reduce morbidity associated with surgery, reduce the duration of a hospital stay and reduce patient recovery times.
In other aspects of the invention, surgical instruments are provided.
The instruments are advantageously configured for use in the methods of treating spinal pseudoarthrosis described herein. In one form of the invention, a cannulated drill is provided that includes an elongated member having a
proximal end, a distal end, an inner surface, and an outer surface. The inner surface defines a lumen that extends along the length of the elongated member and is sized to receive an elongated obturator The distal end of the elongated member has at least one bone cutting edge. The proximal end of the elongated member has a connector configured for matingly engaging a distal end of a syringe to the proximal end of the elongated member. The elongated member is preferably formed of a biocompatible material.
Surgical instrument assemblies are also provided including at least the cannulated drill described herein and a syringe. The syringe has a housing that defines a cavity and has a proximal end and a distal end. The distal end of the syringe is matingly engageable to the proximal end of the elongated member. The lumen of the elongated member and the cavity of the housing are in fluid communication when the distal end of the syringe and the proximal end of the elongated member are matingly engaged.
5 BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 is a side elevation view of one embodiment of a drill provided according to the present invention. FIG. 2 is a first end view of the drill of FIG. 1
FIG. 3 is a side elevation of an alternative embodiment of a drill having a plurality of apertures extending along a length of the drill for use in the present invention.
FIG. 4 is a side elevation view of an elongated obturator for use in a drill according to the present invention.
FIG. 5 is a first end view of the obturator of FIG. 4. FIG. 6A is a side elevation view partially broken away of an obturator/drill assembly according to the present invention.
FIG. 6JB is a first end view of the obturator/drill assembly of FIG. 6. FIG. 7 is a side elevation view of an alternative embodiment of a drill for use in the present invention.
FIG. 8A is an exploded view of a syringe-drill assembly provided according to the present invention.
FIG. 8B is a side elevation view of the syringe-drill assembly of FIG. 8A.
FIG. 8C is an exploded view of an alternative embodiment of a syringe-drill assembly provided according to the present invention.
FIG. 9 is a side elevation view an elongated delivery member having apertures extending along a length of the member provided according to the present invention.
FIG. 10A is a side elevation view of a pair of vertebrae depicting pseudoarthrosis at an intertransverse process fusion site.
FIG. 1 OB is a side elevation view of the pseudoarthrosis of the pair of vertebrae of FIG. 10A with a guide wire inserted into a pseudoarthrotic mass. FIG. 1 1 is an enlarged view of the pseudoarthrosis site of FIG. 10A illustrating a cannula positioned adjacent the treatment site.
FIG. 12 is a side elevation view of the pseudoarthrotic mass of FIG. 1 1 depicting a cannulated drill having an obturator disposed in its lumen.
FIG. 13 is a side elevation view of FIG. 12 depicting a drill in a bored hole in the pseudoarthrotic mass. FIG. 14 is a side elevation view of the pseudoarthrotic mass of FIG. 13 depicting the drill without the obturator.
FIG. 15 is a side elevation view of the pseudoarthrotic mass of FIG. 14 depicting a syringe connected to the drill according to the present invention.
FIG. 16 is a side elevation view of the pseudoarthrotic site of FIG. 15 partially broken away and depicting delivery of an osteoinductive composition into a bored hole in the pseudoarthrotic mass according to the present invention.
FIG. 17 is a side elevation view of the pseudoarthrotic mass of FIG. 11 depicting a plurality of holes bored into the mass according to one embodiment of the present invention.
FIG. 18 is a side elevation view in partial section illustrating a fusion cage between a pair of vertebrae wherein a drill is positioned in a pseudoarthrotic mass located within a fusion cage according to another embodiment of the present invention. FIG. 19 is a cross-section view taken along line 19~19 of FIG. 18, illustrating a intervertebral implant, between adjacent vertebrae depicting a plurality of bore holes drilled in the pseudoarthrotic mass inside the implant chamber, as well as in the superior vertebral bodies, adjacent to the implant.
7 DESCRIPTION OF THE EMBODIMENTS
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications of the invention, and such further applications of the principles of the invention as illustrated herein, being contemplated as would normally occur to one skilled in the art to which the invention relates. The present invention relates to methods and instruments for treating pseudoarthrosis. Pseudoarthrosis, also known as pseudarthrosis, refers to a condition that arises due to an incomplete bone fusion process. With respect to spinal pseudoarthrosis, this includes failure of adjacent vertebrae to fuse or the presence of some other bone discontinuity in the fusion mass. That is, the bone of the spinal fusion is not contiguous, such that a non-union, or a gap between the bone, exists. In a first aspect of the invention, embodiments of methods include delivering to a location of spinal pseudoarthrosis an effective amount of an osteoinductive composition. The composition advantageously includes an osteoinductive factor, such as in a pharmaceutically acceptable carrier. The osteoinductive composition is effective in promoting bone growth to treat the spinal pseudoarthrosis.
In a second aspect of the invention, embodiments of surgical instruments are provided. In one form, a surgical instrument includes a cannulated drill including an elongated member formed of a biocompatible material and having a proximal end, a distal end, an inner surface, and an outer surface. The inner surface defines a lumen that extends along the length of the elongated member and is sized to receive an elongated obturator. The distal end of the elongated member has at least one bone cutting edge. The proximal end of the elongated member has, or otherwise defines, a connector configured to matingly engage a distal end of a syringe. Embodiments of surgical instrument assemblies are also provided that include the drill described herein
and a syringe. In addition or in the alternative, the surgical assemblies can include a cannulated drill and obturator for sliding engagement within an interior region of the cannulated drill. One or more of the surgical assemblies can be provided for delivery of a flowable or injectible osteoinductive composition into a desired treatment site. Embodiments of kits for treating pseudoarthrosis that include a combination of the surgical instruments and/or instrument assemblies described herein are also provided.
As disclosed above, in one aspect of the invention, surgical instruments may be advantageously utilized in a procedure for treating pseudoarthorosis. Embodiments of these instruments will be described first in order to facilitate the discussion herein of the methods of treating spinal pseudoarthrosis. In one embodiment, a surgical instrument includes an elongated channel-forming and delivery member such as a drill 10 as seen in FIGS. 1 and 2. Drill 10 comprises an elongated member 20 having a proximal end 21, a distal end 22, an exterior surface 23 and an inner surface 24. Distal end 22 has at least one bone cutting edge 26, and preferably about two to about four cutting edges for cutting bone. Alternately, the drill may include any device capable of forming a passageway or channel in or adjacent to the site of pseudoarthrosis, such as a piercing device, milling device, etc. Inner surface 24 defines a lumen 25 extending along the length of elongated member 20, typically from proximal end 21 to distal end 22. Lumen 25 is illustrated as a cylindrical channel having a first opening 11 adjacent to proximal end 21, and a second opening 12 proximate to distal end 22 permitting access through the interior of drill 10. Moreover, lumen 25 of elongated member 20 is sized to receive an obturator (not shown). In another embodiment, lumen 25 is sized to receive a guide wire, such as, a K-wire. The guide wire can be selected to be any desired diameter and/or length. The guide wire can be inserted into a treatment site to facilitate desired placement of drill 10 during treatment. Proximal end 21 of elongated member 20 is advantageously configured for mating with a syringe. Proximal end 21 of elongated member 20 may
therefore include, or otherwise define, a connector 27 that matingly engages the distal end of a syringe to proximal end 21 of elongated member 20. The connector may be formed integral with the elongated member or may be separately connected thereto, such as by use of press-fit threaded connectors, adhesives and any other securing methods or combinations thereof. A wide variety of connectors may be utilized, including luer-lock connectors, Moorse taper connectors and snap-lock connectors.
Figure 3 illustrates an alternative embodiment of a drill 10' for use in the present invention. Drill 10' is formed similar to drill 10 and like reference numbers with a prime are used to denote like elements. Drill 10' includes a plurality of apertures 28 extending through exterior surface 23' to inner surface 24'. Preferably, apertures 28 are provided in a desired size, number and location along a length of the drill 10'. In one embodiment, the apertures are sized and located to effectively deposit an osteoinductive material across a pseudoarthrotic region of the spine with minimal or no repositioning of the drill. In the illustrated embodiment a plurality of apertures 28 are located proximate to distal end 22'.
Referring now to FIGS. 4 and 5, one embodiment of a lumen-blocking device such as obturator 30 comprises an elongated member 40 having a proximal end 41, a distal end 42, an outer surface 43 and an inner surface 44. Inner surface 44 defines a lumen 45 that extends along the length of elongated member 40, typically from proximal end 41 to distal end 42. Obturator 30 may be advantageously designed and configured to conform to inner surface 24 of elongated member 20 of drills 10 and/or 10' and/or be slidably received within lumen 25 and/or 25'. Although obturator 30 may be variously shaped, in one form of the invention obturator 30 is cylindrical. For example, obturator 30 is slidably disposed in lumen 20 of drill 10 to provide assembly 35 as best seen in FIG. 6A and FIG. 6B. Obturator 30 can be sized and configured to inhibit material from entering the lumen of the drill during the drilling process.
In other forms of the invention, yet other drills may be utilized. Referring to FIG. 7, a drill 10" is shown. Drill 10" is formed similar to drill 10 and like reference numbers with a double prime are used to denote like elements. Drill 10" advantageously may have a built-in depth gauge 29. Depth gauge 29 can be movably secured to a portion of surface 23" that limits the drilling depth of drill 10". Depth gauge 29 may be positionable during surgery. For example, the surgeon can determine a desired depth to bore into a bone or pseudoarthrotic site using x-ray, Computer Tomography (CT), fluoroscopy or other techniques. The surgeon can then measure a distance from distal end 26" toward proximal end 21 " equal to the desired bore depth.
The surgeon can then position depth gauge 29 at a position 36 from the distal end of drill 10" equal to the desired bore depth. Depth gauge 29 can be secured in the desired position using a set screw, or other locking mechanism.
The drills and obturators described herein may be formed of biocompatible materials. In preferred forms of the invention, the drill and obturator may be formed from metallic materials, including stainless steel, titanium, and alloys thereof. Other suitable materials include nitinol, or other shape memory materials.
In another aspect of the invention, embodiments of surgical instrument assemblies are provided. Referring now to FIG. 8A, in one form of the invention, a surgical instrument assembly 50 includes drill 10 and syringe 60. While drill 10 is illustrated it is understood that any of drills 10, 10' and/or 10" can be included in the assembly. Syringe 60 may be any device capable of delivering an osteoinductive composition. In one embodiment, syringe 60 includes a barrel, or housing, 61 having a proximal end 62 and a distal end 63. Housing 61 defines a cavity, or chamber, 64 for retaining a composition to be delivered. Plunger 66 having a plunger head 67 is disposed in cavity 64 of syringe 60. Distal end 63 defines a connector portion 68, such as a luer-lock connector provided to relesably engage connector 27 of drill 10.
1 1
Referring additionally to FIG. 8B, distal end 63 of syringe 60 is matingly engaged to proximal end 21 of drill 10. When so engaged, chamber 64 of syringe 60 is in fluid communication with lumen 25 of drill 10 to form surgical instrument assembly 50. Syringe 60 may be formed of a material that does not react with osteoinductive compositions, such as polymeric materials, including metal, glass, and synthetic polymers, such as polyalkenes, including polyethylene, polypropylene, poly(vinyl chloride), and polystryrene. Referring to FIG. 8C, an alternative surgical instrument assembly is shown that includes drill 10 and syringe 60'. As above noted while drill 10 is illustrated in assembly 50' any of drills 10, 10' and 10" can be combined with syringe 60'. Syringe 60' is formed similar to syringe 60, and thus like reference numbers denote similar components but are denoted with a prime. Plunger 66' includes one or more threads 68 extending along a length of plunger shaft 69. Threads 68 can facilitate incremental adjustment of plunger 66 in chamber 64, and, consequently, facilitate withdrawing or expulsion of material into or out of chamber 64.
As seen in FIG. 9, in another embodiment, an elongated delivery member 70 fluidly connectable with an osteoinductive material delivery device includes an elongated member 71 having a proximal end 72, a distal end 73, an outer surface 74 and an inner surface 75. Inner surface 75 defines a lumen 76 extending along the length of elongated member 71, typically from proximal end 72 to distal end 73. In one embodiment, distal end 73 can be closed. Alternatively, distal end 73 can include one or more openings extending therethrough providing communication with lumen 76. Furthermore, elongated member 71 may have a plurality of apertures, or other openings or perforations, 78 extending through outer surface 74 anywhere along a length of elongated member 71 , such as adjacent to distal end 73. Proximal end 72 may have a connector 77 for matingly engaging a syringe and may be similar to the connectors 27 described above for the drill 10. In another form, the invention provides methods for treating pseudoarthrosis. The methods may be minimally invasive. For example, an
Claims (38)
1. A method of treating pseudoarthrosis, comprising: identifying a site of spinal pseudoarthrosis; and delivering to a location of the pseudoarthrosis an effective amount of injectible osteoinductive composition, in a pharmaceutically acceptable carrier, effective for promoting bone growth for treating said pseudoarthrosis.
2. The method of claim 1, wherein said osteoinductive composition comprises a bone morphogenetic protein.
3. The method of claim 2, wherein said bone morphogenetic protein is selected from the group consisting of BMP-2, BMP-3, BMP-4,
BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-
13, BMP-14, BMP-15, BMP- 16, BMP-17, BMP- 18, a mixture thereof and a heterodimer thereof.
4. The method of claim 3, wherein said bone morphogenetic protein is a recombinant protein.
5. The method of claim 4, wherein said recombinant protein is selected from the group consisting of rhBMP-2, rhBMP-7, a mixture thereof and a heterodimer thereof.
6. The method of claim 1, wherein said osteoinductive composition comprises an adenovirus capable of eliciting intracellular production of a LIM mineralization protein.
22
7. The method of claim 6, wherein said LIM mineralization protein is LMP-1.
8. The method of claim 1, wherein said carrier is a calcium phosphate cement.
9. The method of claim 1, wherein said carrier is selected from the group consisting of a resorbable cement, carboxymethylcellulose, polylactic acid, polyglycolic acid, alternating copolymers of polylactic acid and polyglycolic acid, hyaluronic acid, glycosaminoglycan and mixtures thereof.
10. The method of claim 1, wherein said delivering comprises: advancing an elongated member having a proximal end, a distal end and a lumen extending longitudinally therethrough to said location of pseudoarthrosis; and advancing said osteoinductive composition through said lumen of said elongated member to said location of pseudoarthrosis.
11. The method of claim 10, wherein said elongated member is connected to a osteoinducive composition delivery device.
12. The method of claim 10, wherein said elongated member comprises at least one bone removing surface.
13. The method of claim 1 , further comprising forming at least one channel in a tissue mass at the location of the spinal pseudoarthrosis.
23
14. The method of claim 1, wherein said location of pseudoarthrosis has a pseudoarthrotic mass, said method further comprising creating a channel in the bone adjacent the pseudoarthrotic mass, and delivering said osteoinductive composition such that it extends from the channel within the bone on one side of the fibrous tissue of the pseudoarthrotic mass, through a fibrous tissue and into the channel created in the bone on the opposing side of the fibrous tissue.
15. The method of claim 1 , wherein said location of spinal pseudoarthrosis has a pseudoarthrotic mass and said pseudoarthrotic mass is located at an interbody fusion site.
16. The method of claim 1, wherein said location of pseudoarthrosis has a pseudoarthrotic mass and said pseudoarthrotic mass is located at a transverse process fusion site of one or more vertebral bodies.
17. The method of claim 1 wherein said pseudoarthrotic mass is located proximal to a bone fracture.
18. The method of claim 17 wherein the bone fracture has at least partially healed.
19. The method of claim 1 wherein said pseudoarthrotic mass is located proximal to a long bone.
24
20. A method of treating spinal pseudoarthrosis in a patient, comprising: advancing a first elongated member having a proximal end, a distal end and a lumen extending longitudinally therethrough to a location of spinal pseudoarthrosis in the patient; and advancing an injectible osteoinductive composition through said lumen of said first elongated member to said location, said osteoinductive composition comprising an osteoinductive factor in a pharmaceutically acceptable carrier.
21. The method of claim 20, wherein said advancing a first elongated member comprises advancing said first elongated member into fibrous tissue of a pseudoarthrotic mass of said location.
22. The method of claim 20, wherein said first elongated member has a distal end with at least one bone cutting edge.
23. The method of claim 20, wherein said first elongated member has a plurality of apertures extending along at least a portion of a length of said first elongated member.
24. The method of claim 20, wherein said location of spinal pseudoarthrosis has a pseudoarthrotic mass, said method further comprising creating a channel in a bone adjacent the pseudoarthrotic mass, and delivering said osteoinductive composition such that it extends from the channel within the bone on one side of a fibrous tissue of the pseudoarthrotic mass, through the fibrous tissue and into the channel created in the bone on the other side of the fibrous tissue.
25
25. The method of claim 20, wherein said method further comprises: advancing a second elongated member to a location of spinal pseudoarthrosis prior to advancing said first elongated member, said second member having a proximal end, a distal end and a lumen extending longitudinally therethrough, said distal end having at least one bone cutting edge; and retracting said second elongated member.
26. The method of claim 25, wherein said second elongated member has a plurality of apertures extending along at a length of said second elongated member.
27. A method of treating spinal pseudoarthrosis in a patient, comprising: advancing an elongated member into a pseudoarthrotic mass in said patient, said elongated member having a proximal end, a distal end and a lumen extending longitudinally therethrough, said distal end of said member having at least one bone cutting edge; and advancing an osteoinductive composition through said lumen of said elongated member to said pseudoarthritic mass, said osteoinductive composition extending across said pseudoarthrotic mass, said osteoinductive composition comprising an osteoinductive factor in a pharmaceutically acceptable carrier and effective in promoting bone growth for treating said spinal pseudoarthrosis.
28. The method of claim 27, wherein said osteoinductive composition includes cells transformed with a nucleotide sequence encoding an osteoinductive factor, said nucleotide sequence operably connected to a promoter sequence, whereby said osteoinductive factor is produced in vivo.
26
29. A cannulated drill, comprising an elongated member formed of a biocompatible material and having a proximal end, a distal end, an inner surface, and an outer surface, said inner surface defining a lumen, said lumen extending along the length of said elongated member and sized to receive an elongated obturator, said distal end of said elongated member having at least one bone cutting edge, said proximal end of said elongated member having a connector configured for matingly engaging a distal end of a syringe to said proximal end of said elongated member.
30. The drill of claim 29, wherein said elongated member is cylindrical.
31. The drill of claim 29, wherein said elongated member is formed of a biocompatible metallic material.
32. The drill of claim 27, further comprising an elongated obturator, said obturator slidably disposed in said lumen of said elongated member.
33. The drill of claim 27, wherein said elongated member has a plurality of apertures extending along its length.
27
34. A surgical instrument assembly, comprising: a cannulated drill, said drill comprising an elongated member formed of a biocompatible material and having a proximal end, a distal end, an inner surface, and an outer surface, said inner surface defining a lumen, said lumen extending along the length of said elongated member, said distal end having at least one bone cutting edge, said proximal end having a connector for matingly engaging a distal end of a syringe to said proximal end of said elongated member; and a syringe, said syringe having a housing defining a cavity, said housing having a proximal end and a distal end, said distal end of said syringe matingly engageable to said proximal end of said elongated member, said lumen of said elongated member and said cavity of said housing in fluid communication when said distal end of said syringe is matingly engaged to said proximal end of said elongated member.
35. The assembly of claim 34, further comprising a plunger having a plunger head, said cavity of said housing adapted to receive said plunger.
36. The assembly of claim 34, wherein said connector is a luer-lock connector.
37. The assembly of claim 34, wherein said elongated member has a plurality of apertures extending along a length of said elongated member.
28
38. A kit for treating pseudoarthrosis, comprising: a cannulated drill, said drill comprising an elongated member formed of a biocompatible material and having a proximal end, a distal end, an inner surface, and an outer surface, said inner surface defining a lumen, said lumen extending along the length of said elongated member, said distal end having at least one bone cutting edge, said proximal end having a connector for matingly engaging a distal end of a syringe to said proximal end of said elongated member; an elongated obturator sized to fit within said lumen of said drill; and a syringe, said syringe having a housing defining a cavity, said housing having a proximal end and a distal end, said distal end of said syringe matingly engageable to said proximal end of said elongated member, said lumen of said elongated member and said cavity of said housing in fluid communication when said distal end of said syringe is matingly engaged to said proximal end of said elongated member.
1/11
2/11
Fig. 6B
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24295000P | 2000-10-24 | 2000-10-24 | |
| US60/242,950 | 2000-10-24 | ||
| PCT/US2001/045479 WO2002034113A2 (en) | 2000-10-24 | 2001-10-24 | Methods and instruments for treating pseudoarthrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002220069A1 true AU2002220069A1 (en) | 2002-07-11 |
| AU2002220069B2 AU2002220069B2 (en) | 2005-12-15 |
Family
ID=22916758
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002220069A Ceased AU2002220069B2 (en) | 2000-10-24 | 2001-10-24 | Methods and instruments for treating pseudoarthrosis |
| AU2006902A Pending AU2006902A (en) | 2000-10-24 | 2001-10-24 | Methods and instruments for treating pseudoarthrosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006902A Pending AU2006902A (en) | 2000-10-24 | 2001-10-24 | Methods and instruments for treating pseudoarthrosis |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1335771A4 (en) |
| JP (1) | JP2004512078A (en) |
| AU (2) | AU2002220069B2 (en) |
| CA (1) | CA2426402A1 (en) |
| WO (1) | WO2002034113A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US8002775B2 (en) | 2001-10-24 | 2011-08-23 | Warsaw Orthopedic, Inc. | Methods and instruments for treating pseudoarthrosis |
| JP2005524710A (en) * | 2002-05-06 | 2005-08-18 | ジェネンテック・インコーポレーテッド | Use of VEGF in the treatment of bone defects |
| FR2860422A1 (en) * | 2003-10-02 | 2005-04-08 | Emmanuel Berque | Biocompatible adhesive substance applying device for prosthetic implant, has inner valve for closing catheters distal end and for opening distal end when manual thrust is applied on piston of syringe with respect of body |
| EP1896046A2 (en) * | 2005-03-22 | 2008-03-12 | Warsaw Orthopedic, Inc. | Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1) |
| US8083722B2 (en) | 2005-04-29 | 2011-12-27 | Warsaw Orthopedic, Inc | Instrumentation for injection of therapeutic fluid into joints |
| US7850656B2 (en) | 2005-04-29 | 2010-12-14 | Warsaw Orthopedic, Inc. | Devices and methods for delivering medical agents |
| WO2010040076A2 (en) * | 2008-10-02 | 2010-04-08 | Trans1, Inc. | Method and apparatus for bone graft insertion |
| US9101409B2 (en) * | 2010-03-09 | 2015-08-11 | National University Corporation Kobe University | Inter-spinous process implant |
| IT201900003947A1 (en) * | 2019-03-19 | 2020-09-19 | Mt Ortho S R L | Granule in biocompatible metal material for vertebroplasty. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4013080A (en) * | 1974-10-03 | 1977-03-22 | Froning Edward C | Cannula connector and direction indicator means for injection system |
| JPS58155867A (en) * | 1982-03-12 | 1983-09-16 | テルモ株式会社 | Drill needle and medical container with drill needle |
| US6241734B1 (en) * | 1998-08-14 | 2001-06-05 | Kyphon, Inc. | Systems and methods for placing materials into bone |
| JP3424049B2 (en) * | 1994-03-09 | 2003-07-07 | 山之内製薬株式会社 | Bone formation implant |
| GB9407135D0 (en) * | 1994-04-11 | 1994-06-01 | Aberdeen University And Plasma | Treatment of osteoporosis |
| JP3125579B2 (en) * | 1994-05-24 | 2001-01-22 | 三菱マテリアル株式会社 | Biological cement filling equipment |
| US5584839A (en) * | 1994-12-12 | 1996-12-17 | Gieringer; Robert E. | Intraarticular drill guide and arthroscopic methods |
| US5676976A (en) * | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US6039762A (en) * | 1995-06-07 | 2000-03-21 | Sdgi Holdings, Inc. | Reinforced bone graft substitutes |
| US5779708A (en) * | 1996-08-15 | 1998-07-14 | Cyberdent, Inc. | Intraosseous drug delivery device and method |
| ATE269720T1 (en) * | 1996-10-16 | 2004-07-15 | Etex Corp | METHOD FOR PRODUCING LOW CRYSTALLINE CALCIUM PHOSPHATE AND METHOD FOR USE THEREOF |
| IL128261A0 (en) * | 1999-01-27 | 1999-11-30 | Disc O Tech Medical Tech Ltd | Expandable element |
| CA2297489A1 (en) * | 1997-07-30 | 1999-02-11 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
| JPH11313674A (en) * | 1998-04-30 | 1999-11-16 | Hoechst Marion Roussel Kk | Human BMP-4 promoter and method for searching for bone-related substances using the same |
| AU3498300A (en) * | 1999-02-22 | 2000-09-14 | Peter A. Guagliano | Method of treating an intervertebral disk |
-
2001
- 2001-10-24 AU AU2002220069A patent/AU2002220069B2/en not_active Ceased
- 2001-10-24 CA CA002426402A patent/CA2426402A1/en not_active Abandoned
- 2001-10-24 AU AU2006902A patent/AU2006902A/en active Pending
- 2001-10-24 EP EP01988541A patent/EP1335771A4/en not_active Withdrawn
- 2001-10-24 JP JP2002537173A patent/JP2004512078A/en active Pending
- 2001-10-24 WO PCT/US2001/045479 patent/WO2002034113A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8002775B2 (en) | Methods and instruments for treating pseudoarthrosis | |
| US11969354B2 (en) | Medical implant for fixation and integration with hard tissue | |
| CA2269342C (en) | Spinal spacer | |
| US7329259B2 (en) | Articulating spinal implant | |
| EP1578315B1 (en) | Apparatus for spinal distraction and fusion | |
| US7727263B2 (en) | Articulating spinal implant | |
| JP4159255B2 (en) | Spinal fixation implant | |
| US20090171394A1 (en) | Devices And Methods For The Treatment Of Facet Joint Disease | |
| JP2002534211A5 (en) | ||
| AU2002220069B2 (en) | Methods and instruments for treating pseudoarthrosis | |
| EP3203941B1 (en) | Bone scaffold improvements | |
| AU2002220069A1 (en) | Methods and instruments for treating pseudoarthrosis | |
| AU773116B2 (en) | Spinal spacer | |
| NZ731593B2 (en) | Bone scaffold improvements |